Dr. Rampal on Pelabresib With or Without Ruxolitinib in Myelofibrosis
In Partnership With:
Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis.
Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the investigation of pelabresib (CPI-0610) with or without ruxolitinib (Retuxan) in patients with myelofibrosis.
The phase 1/2 MANIFEST trial (NCT02158858) examined the use of pelabresib with and without ruxolitinib in patients with myelofibrosis. The MANIFEST study featured 3 arms: the combination of pelabresib and ruxolitinib in previously untreated patients, single-agent pelabresib in patients who were already receiving ruxolitinib, and single-agent pelabresib arm for patients previously treated with a JAK inhibitor, Rampal explains.
Data showed that in the up-front treatment setting, patients treated with the combination experienced a benefit in spleen volume response—defined as a 35% or greater reduction in spleen volume—compared favorably with historical data for single-agent ruxolitinib, Rampal adds.
The phase 3 MANIFEST-2 trial (NCT04603495) will further investigate the combination of pelabresib and ruxolitinib vs placebo plus ruxolitinib in patients with myelofibrosis who have not received prior treatment with a JAK inhibitor, Rampal concludes.
